30
Participants
Start Date
May 29, 2025
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2026
Pembrolizumab
Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
Carboplatin
Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
Paclitaxel
Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
RECRUITING
Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña
RECRUITING
Hospital Universitari Dexeus, Barcelona
RECRUITING
Hospital Universitari Vall D'Hebron, Barcelona
RECRUITING
Institut Català d' Oncologia Girona (ICO), Girona
RECRUITING
Hospital Universitario Clínico San Cecilio de Granada, Granada
RECRUITING
Hospital Beata María Ana, Madrid
RECRUITING
Hospital Cínico San Carlos, Madrid
RECRUITING
Hospital Universitario de Navarra, Pamplona
RECRUITING
Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela
RECRUITING
Hospital Universitario Virgen del Rocío, Seville
RECRUITING
Hospital Arnau de Vilanova de Valencia, Valencia
Merk Sharp & Dohme España S.A.
UNKNOWN
MedSIR
OTHER